Anticancer Drugs as Inhibitors of Two Polymorphic Cytochrome P450 Enzymes, Debrisoquin and Mephenytoin Hydroxylase, in Human Liver Microsomes

Cancer Research

Volumn 49, Issue 1, 1989, Pages 68-71

  Relling, Mary V ^b   Evans, William E ^b   Fonné Pfister, Raymonde ^a   Meyer, Urs A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; DEBRISOQUINE; ENZYME INHIBITOR; ETOPOSIDE; IFOSFAMIDE; MEPHENYTOIN; MITOFLAXONE; OXYGENASE; TENIPOSIDE; VINBLASTINE; VINCRISTINE;

HUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; ETOPOSIDE; FLAVONES; HUMAN; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; POLYMORPHISM (GENETICS); SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TENIPOSIDE;

EID: 0024529709     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Evans, W. E. Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. Blut, 56:241-248, 1988.
2. Rodman, J. H., Abromowitch, M., Sinkule, J. A., Rivera, G. K., and Evans, W. E. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a Phase I trial. J. Clin. Oncol., 5:1007-1014, 1987.
3. Bertino, J. R. Blood levels of cancer chemotherapeutic agents and clinical outcome. J. Clin. Oncol., 5:996, 1987.
4. Crom, W. R., Glynn-Barnhart, A. M., Rodman, J. H., et al. Pharmacokinetics of anticancer drugs in children. Clin. Pharmacokin., 12:168-213, 1987.
5. Erlichman, C., et al. Therapeutic drug monitoring in oncology, problems and potential in antineoplastic therapy. Clin. Pharmacokin., 13:205-227, 1987.
6. Eichelbaum, M., Spannbrucker, N., Steincke, B., and Dengler, H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol., 16:183-187, 1979.
7. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R., and Smith, R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet. 2: 584-586, 1977.
8. Price-Evans, D. A. P. Therapy. In: W. Kalow, H. W. Goedde, and D. P. Agarnal (eds.), Ethnic Differences in Reactions to Drugs and Xenobiotics, 491-526. New York: Alan R. Liss, 8 1986.
9. Wedlund, P. J., Aslanian, W. S., McAllister, C. G., Wilkinson, G. R., and Branch, R. A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther., 36:773-780, 1984.
10. Kalow, W. The genetic defect of mephenytoin hydroxylation. Xenobiotica, 16:379-390, 1986.
11. Kupfer, A., Desmond, P., Schenker, S., and Branch, R. Family study of a genetically determined deficiency of mephenytoin hydroxylation in man. Pharmacologist, 21:173, 1979.
12. Gonzales, F. G., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P., and Meyer, U. A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (Lond.), 331:442-446, 1988.
13. Zanger, U. M., Vilbois, F., Hardwick, J. P., and Meyer, U. A. Absence of hepatic cytochrome P 450 bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry, 27:5447-5454, 1988.
14. Meier, U. T., Dayer, P., Male, P. J., Kronbach, T., and Meyer, U. A. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin. Pharmacol. Ther., 38:488-494, 1985.
15. Kupfer, A., and Branch, R. A. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. CUn. Pharmacol. Ther., 38: 414-418, 1985.
16. Guengerich, F. P. Roles of cytochrome P 450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res., 48: 2946-2954, 1988.
17. Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., and Hetzel, M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (Lond.), 312:169-170, 1984.
18. Idle, J. R., Mahgoub, A., Sloan, T. P., Smith, R. L., Mbanefo, C. O., and Bababunmi, E. A. Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer. Cancer Lett., 11:331-338, 1981.
19. Kaisary, A., Smith, P., Jaczq, E., et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res., 47:5488-5493, 1987.
20. Meier, P. J., Mueller, H. K., Dick, B., and Meyer, U. A. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology, 85:682-692, 1983.
21. Kronbach, T., Mathys, D., Gut, J., Catin, T., and Meyer, U. A. High performance liquid chromatographic assays for bufuralol 1 '-hydroxylase, debrisoquine 4'-hydroxylase, and dextromethorphan β-demethylase in mi-crosomes and purified cytochrome P-450 isozymes of human liver. Anal. Biochem., 162:24-32, 1987.
22. Fonne-Pfister, R., and Meyer, U. A. Xenobiotic and endobiotic inhibitors of cytochrome P 450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem. Pharmacol., 37: 3829-3836, 1988.
23. Meier, U. T., Kronbach, T., and Meyer, U. A. Assay of mephenytoin metabolism in human microsomes by high performance liquid chromatography. Anal. Biochem., 151:286-291, 1985.
24. Otton, S. V., Inaba, T., and Kalow, W. Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci., 34:73-80, 1984.
25. Inaba, T., Jurima, M., Mahon, W. A., and Kalow, W. In vitro inhibition studies of two isozymes of human liver cyctochrome P-450, mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab. Dispos., 13:443-448, 1985.
26. Hall, S. D., Guengerich, F. P., Branch, R. A., and Wilkinson, G. R. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J. Pharmacol. Exp. Ther., 240:216-222, 1987.
27. Gut, J., Catin, T., Dayer, P., Kronbach, T., Zanger, U., and Meyer, U. A. Debrisoquine/sparteine-type polymorphism of drug oxidation. J. Biol. Chem., 261:11734-11743, 1986.
28. Guengerich, F. P., Muller-Enoch, D., and Blair, I. A. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol., 30:287-295, 1987.
29. Mikus, G., Ha, H. R., Vozeh, S., et al. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine. Eur. J. Clin. Pharmacol., 31:69-72, 1986.
30. Clark, P. I., and Slevin, M. L. The clinical pharmacology of etoposide and teniposide. Clin. Pharmacoldn., 12:223-252, 1987.
31. Van Maanen, J. M. S., De Vries, J., Pappie, D., et al. Cytochrome P 450-mediated 0-demethylation: a route in the metabolic activation of etoposide. Cancer Res., 47:4658-4662, 1987.
32. Sinha, B. K., Trush, M. A., and Kalyanaraman, B. Microsomal interactions and inhibition of lipid peroxidation by etoposide: implications for mode of action. Biochem. Pharmacol., 34:2036-2040, 1985.
33. Kerr, D. J., Kaye, S. B., Cassidy, J., et al. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res., 47:6776-6781, 1987.
34. Friedman, O. M., Myles, A., and Colvin, M. Cyclophosphamide and related phosphoramide mustards: current status and future prospects. Adv. Cancer Chemother., 1:143-204, 1986.